# Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients

> **NCT06219239** · NA · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 3 (estimated)

## Conditions studied

- Transfusion-dependent Beta-Thalassemia

## Interventions

- **GENETIC:** KL003 cell injection Drug Product

## Key facts

- **NCT ID:** NCT06219239
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-04
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06219239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06219239, "Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06219239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*